| TRADING CENTER |
| Cubist Pharmaceuticals Completes Acquisition Of Calixa Therapeutics - Business Wire | |
| Cubist's Acquisition to Add Value - Analyst Blog - Zacks.com | |
| Cubist Pharmaceuticals to Acquire Calixa Therapeutics - Business Wire | |
| Trial Date Set for CUBICIN® Patent Litigation - Business Wire | |
| Cubist Pharmaceuticals Closes Enrollment Early in CONSERV™-1 and CONSERV-2 Ph. 2 Tr... - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 57.42 | 0.00 / 0.00% | 10.98 |
| GILD | Gilead Sciences Inc | 43.00 | 0.00 / 0.00% | 16.60 |
| CELG | Celgene Corporation | 56.38 | 0.00 / 0.00% | 67.93 |
| 2008 Revenue: | $433.6 M | Headquarters: Lexington, MA |
| Employees: | 554 | CEO: Michael W. Bonney |
| Net Income: | $169.8 M | Industry: Biotechnology |
| Market Cap: | $1.1 B | Website: www.cubist.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| CBST | 19.04 | 0.00 / 0.00% | 19.04 | 0.00 | 0.00 | Profile Chart News |